4lbt: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Endothiapepsin in complex with 100mM acylhydrazone inhibitor== | ==Endothiapepsin in complex with 100mM acylhydrazone inhibitor== | ||
<StructureSection load='4lbt' size='340' side='right' caption='[[4lbt]], [[Resolution|resolution]] 1.25Å' scene=''> | <StructureSection load='4lbt' size='340' side='right'caption='[[4lbt]], [[Resolution|resolution]] 1.25Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4lbt]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Cryphonectria_parasitica Cryphonectria parasitica]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LBT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4LBT FirstGlance]. <br> | <table><tr><td colspan='2'>[[4lbt]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Cryphonectria_parasitica Cryphonectria parasitica]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LBT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4LBT FirstGlance]. <br> | ||
| Line 27: | Line 27: | ||
[[Category: Cryphonectria parasitica]] | [[Category: Cryphonectria parasitica]] | ||
[[Category: Endothiapepsin]] | [[Category: Endothiapepsin]] | ||
[[Category: Large Structures]] | |||
[[Category: Heine, A]] | [[Category: Heine, A]] | ||
[[Category: Klebe, G]] | [[Category: Klebe, G]] | ||
Revision as of 12:22, 3 April 2019
Endothiapepsin in complex with 100mM acylhydrazone inhibitorEndothiapepsin in complex with 100mM acylhydrazone inhibitor
Structural highlights
Publication Abstract from PubMedStructure-based design (SBD) can be used for the design and/or optimization of new inhibitors for a biological target. Whereas de novo SBD is rarely used, most reports on SBD are dealing with the optimization of an initial hit. Dynamic combinatorial chemistry (DCC) has emerged as a powerful strategy to identify bioactive ligands given that it enables the target to direct the synthesis of its strongest binder. We have designed a library of potential inhibitors (acylhydrazones) generated from five aldehydes and five hydrazides and used DCC to identify the best binder(s). After addition of the aspartic protease endothiapepsin, we characterized the protein-bound library member(s) by saturation-transfer difference NMR spectroscopy. Cocrystallization experiments validated the predicted binding mode of the two most potent inhibitors, thus demonstrating that the combination of de novo SBD and DCC constitutes an efficient starting point for hit identification and optimization. Structure-based design of inhibitors of the aspartic protease endothiapepsin by exploiting dynamic combinatorial chemistry.,Mondal M, Radeva N, Koster H, Park A, Potamitis C, Zervou M, Klebe G, Hirsch AK Angew Chem Int Ed Engl. 2014 Mar 17;53(12):3259-63. doi: 10.1002/anie.201309682. , Epub 2014 Feb 14. PMID:24532096[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||||